Legal
← 실적 발표
01
02
03
04 05 06
톤
AI
A1 A2 A3 A4 A5
PFE
FY2026 Q1
개선
Pfizer, Inc. 실적 발표
Buzzberg 분석
Vindamax settlements push post-2028 growth visibility to high single-digit CAGR
Pfizer reported strong Q1 2026 results with revenues exceeding expectations. Management reiterated FY2026 guidance and highlighted a robust pipeline, particularly in obesity and oncology, plus legal wins improving the post-2028 growth outlook. Q1 revenues reached $14.5 billion, a 2% operational increase; adjusted EPS was $0.75, exceeding expectations.
Buzzberg 분석 Vindamax settlements push post-2028 growth visibility to high single-digit CAGR Pfizer reported strong Q1 2026 results with revenues exceeding expectations. Management reiterated FY2026 guidance and highlighted a robust pipeline, particularly in obesity and oncology, plus legal wins improving the post-2028 growth outlook. Q1 revenues reached $14.5 billion, a 2% operational increase; adjusted EPS was $0.75, exceeding expectations. 전체 분석 보기분석 접기
Pfizer reported strong Q1 2026 results with revenues exceeding expectations. Management reiterated FY2026 guidance and highlighted a robust pipeline, particularly in obesity and oncology, plus legal wins improving the post-2028 growth outlook. Q1 revenues reached $14.5 billion, a 2% operational increase; adjusted EPS was $0.75, exceeding expectations.
- FY2026 guidance maintained: revenue of $59.5-62.5 billion and adjusted EPS of $2.80-3.00.
- Legal settlements on Vindamax and Comirnaty contracts improve post-2028 cash flow and support dividend.
- Obesity program (Medcera) advancing with 10 phase 3 studies planned; first approval targeted in 2028.
매출$14.451B-18% 전분기 대비
주당순이익(EPS)$0.75+14% 전분기 대비
매출총이익률67.26%보고값
영업이익률27.9%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Obesity
Pfizer targets 2028 first approval for monthly obesity portfolio with 10 phase 3 starts
Vaccines
Adult vaccine strategy leapfrogs to 35-serotype fifth-generation candidate
핵심 내용 3개 더 보기
Legal
Belgian court ruling on Comirnaty supports future EPS and cash flow
Guidance
Q1 strength was enough to consider raising guidance, but held on COVID seasonality
Commercial
Launched and acquired products grew 22% operationally in Q1
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $14.451B | -18% 전분기 대비 |
| 주당순이익(EPS) | $0.75 | +14% 전분기 대비 |
| 매출총이익률 | 67.26% | 보고값 |
| 영업이익률 | 27.9% | 보고값 |
| 잉여현금흐름 | $2.179B | -52% 전분기 대비 |
| 자본지출 | $0.436B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 주당순이익(EPS) | FY2026 | $2.80–$3.00 | $2.90 | 유지 |
| 매출총이익률 | FY2026 | 75% | 75% | 제시 |
| 매출 | FY2026 | $59.5B–$62.5B | $61B | 유지 |
| 매출 | FY2029 | 7%–9% | 8% | 신규 제시 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management emphasized a strong start, repeated 'disciplined execution,' reaffirmed full-year guidance, and projected increased visibility into post-2028 growth and cash flow, grounding an upbeat outlook.
경영진의 AI 분석
Management said AI is a key strategic priority embedded across R&D, commercial, manufacturing, and core enterprise functions. They are pairing frontier AI tools with training to compress discovery and development timelines and unlock insights from Pfizer's vast translational and clinical data.
아래에 언급된 기업 7개 모두 표시
기업발표 이후 수익률
파트너
파트너
Dave Denton
Pfizer's gross margin commentary confirms ongoing 50-50 profit share with BioNTech for Comirnaty, underscoring alignment of interests and shared financial exposure.
근거
“Comirnaty, which has a 50-50 profit split with our partner, BioNTech.”
파트너
Dr. Albert Bourla
Pfizer highlights its licensing agreement with Bayer as a strategic asset supporting its R&D pipeline and future growth, indicating deepening partnership.
근거
“opportunities we have added through strategic moves, such as our acquisition of Metcera and our licensing agreements with 3S Bayer and Yalthal.”
경쟁사
경쟁사
Chris Bosso
Pfizer's PD-1/VEGF bispecific (4404) competes with Roche's bevacizumab-based therapies, claiming higher VEGFA affinity.
근거
“as well as high affinity affinity than what's seen with bevacizumab or that's seen with um competitive and vgfpd1 molecules.”
경쟁사
Amir (Head of U.S. Vaccines)
Pfizer will advance directly to a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes, aiming to maintain leadership in the adult market. — This next-gen vaccine targets broader serotype coverage, strengthening Pfizer's competitive position against Merck's adult pneumococcal vaccine.
근거
“Prevnar Adult, even after many months of competition from Mark, holding share steady at 70%.”
경쟁사
Alexander (Head of International Contracts & Market Access)
Pfizer's PD-1/VEGF bispecific (4404) shows differentiated early data with high VEGFA affinity, potentially strengthening its lung cancer portfolio. — This could impact the competitive landscape in non-small cell lung cancer, challenging existing PD-1/angiogenesis combo therapies.
근거
“Lilly really introduced their asset in the beginning of last year. So it's not like we're coming many years after the introduction of those assets.”
투자 대상
투자 대상
Dr. Albert Bourla
Pfizer's Seagen acquisition is delivering strong oncology revenue growth, validating strategic investment in ADCs.
근거
“The 20% year-over-year operational revenue growth in the quarter of our seeds and products shows that we have made good progress in deepening our presence within the oncology community.”
공급망
공급망
Dr. Albert Bourla
Pfizer's obesity program (Medcera) is advancing rapidly, with 10 phase three studies planned this year and a target first approval in 2028. — This signals a major push into the obesity market, intensifying competition with Lilly and Novo Nordisk.
근거
“We intend to advance 10 phase three studies this year, and we are targeting a first approval in 2028 from a portfolio that includes ultra-long-acting peptides.”
외부 신호
공급망 알파 · 5발표 이후 수익률
Pfizer's Vindamax patent settlement extends exclusivity, significantly improving post-2028 revenue CAGR to high single digits.
Pfizer will advance directly to a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes, aiming to maintain leadership in the adult market.
Pfizer's obesity program (Medcera) is advancing rapidly, with 10 phase three studies planned this year and a target first approval in 2028.
Pfizer's PD-1/VEGF bispecific (4404) shows differentiated early data with high VEGFA affinity, potentially strengthening its lung cancer portfolio.
Pfizer's robust BD capacity of ~$7 billion combined with successful legal settlements could enable further strategic acquisitions or share buybacks.
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 7개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.